Business
Novavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M™ Adjuvant as Potential Component in Vaccine Research
GAITHERSBURG, Md., June 5, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™
About this update from Novavax, Inc.
[{"type":"text","content":"GAITHERSBURG, Md., June 5, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, has signed a three-year agreement with the Bill & Melinda Gates Medical Research Institute to provide its adjuvant for use in preclinical vaccine research.\n\"We are excited to partner with the Bill & Melinda Gates Medical Research Institute to include our unique technology in their public health-focused vaccine research efforts,\" said John C. Jacobs, President and Chief Executive Officer, Novavax. \"Our Matrix-M™ adjuvant is proven to enhance and broaden the immune system response when included in vaccines and is already a key component of COVID and malaria vaccines on the market today. We look forward to partnering more broadly with a variety of organizations so that our technology can benefit vaccine development across many disease areas.\"\n\"The Bill & Melinda Gates Medical Research Institute is committed to developing biomedical interventions that address global health concerns for those in the greatest need,\" said Emilio Emini, PhD, chief executive officer of the Bill & Melinda Gates Medical Research Institute. \"We look forward to working with Novavax's Matrix-M™ adjuvant in some of our early-stage vaccine programs.\"\nThe Matrix-M adjuvant is a key component of Novavax's COVID vaccine and its development-stage vaccines including influenza and COVID and influenza combined. In addition, the adjuvant is being used through partnerships in clinical and preclinical programs across the world for the development of both human and animal vaccines.\nAbout Matrix-M™ AdjuvantWhen added to vaccines, Novavax's patented saponin-based Matrix-M adjuvant enhances the immune system response, making it broader, and more durable. The Matrix-M adjuvant stimulates the entry of antigen-presenting cells at the injection site and enhances antigen presentation in local lymph nodes.\nAbout NovavaxNovavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to e...